comparemela.com

Iological Therapy In Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Perioperative Nivolumab Improves EFS in Resectable NSCLC

Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.

United statesMarina garassinoBristol myers squibbTina casconeThoracic oncology programUniversity of chicagoEuropean society for medical oncologyEuropean societyMedical oncologyCancer medicineCancer centerNon small cell lung cancerLung cancerUng carcinomaAncer lungBiologic therapy in cancer

FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC

The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.

Mark awadDrug administrationDana farber cancer instituteBristol myers squibbLung cancerUng carcinomaAncer lungNon small cell lung cancerAlignant neoplasiaCombination chemotherapyBiologic therapy in cancerIological therapy in cancerIologics cancerBiologic therapyClinical researchClinical trials

Yescarta Label Updated: Prophylactic Steroids to Prevent CRS

However, labeling notes a potential increase in neurologic toxicity.

United statesFrank neumannB cell lymphomaAdverse effectsSide effectsChimeric antigen receptort cell therapyChimeric antigen receptorsHimeric immunoreceptorsHimerict cell receptorsRtificialt cell receptorsAr tBiologic therapyBiologic therapy in cancerIological therapy in cancerIologics cancerClinical research

ICIs for NSCLC: Patients With ILD Show Greater Risk

Immune checkpoint inhibitors can be effective in patients with non-small cell lung cancer and mild interstitial lung disease, but with a greater risk.

United statesYuan chengJarushka naidooKarthik sureshUniversity first hospitalJohns hopkins school of medicineSidney kimmel comprehensive cancer centerPeking university first hospitalMedscape medicalEast asianJohns hopkins schoolLung cancerUng carcinomaAncer lungInterstitial lung diseaseNon small cell lung cancer

Updated NCCN Guidelines Now Include Zanubrutinib for WM

The new second-generation BTK inhibitor zanubrutinib is a preferred regimen for the treatment of symptomatic Waldenstrom s macroglobulinemia.

United statesConstantine tamSteven treonInternational workshop on waldenstrom macroglobulinemiaInternational waldenstrom macroglobulinemia foundation educational forumPeter maccallum cancer centreDrug administrationHealth canadaHarvard medical schoolNational comprehensive cancer networkInternational waldenstromMacroglobulinemia foundation educationalMedscape medical newsInternational workshopWaldenstrom hypergammaglobulinemiaAlignant neoplasia

vimarsana © 2020. All Rights Reserved.